Published in Ann Oncol on March 16, 2010
Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Support Care Cancer (2012) 1.17
Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2014) 0.84
Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trial. Biol Blood Marrow Transplant (2012) 0.83
Clinical applications of palifermin: amelioration of oral mucositis and other potential indications. J Cell Mol Med (2013) 0.81
A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function. Biol Blood Marrow Transplant (2012) 0.80
Efficacy of palifermin in the hematopoietic stem cell transplant setting. J Adv Pract Oncol (2013) 0.75
Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. Bone Marrow Transplant (2016) 0.75
Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy. Lasers Med Sci (2017) 0.75
Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science (2000) 7.99
New techniques for purifying large DNAs and studying their properties and packaging. Cold Spring Harb Symp Quant Biol (1983) 6.35
Pilus genes of Neisseria gonorrheae: chromosomal organization and DNA sequence. Proc Natl Acad Sci U S A (1984) 5.37
The repertoire of silent pilus genes in Neisseria gonorrhoeae: evidence for gene conversion. Cell (1986) 4.48
Systematic mutagenesis of the Helicobacter pylori cag pathogenicity island: essential genes for CagA translocation in host cells and induction of interleukin-8. Mol Microbiol (2001) 3.75
Genetic analysis of the Helicobacter pylori vacuolating cytotoxin: structural similarities with the IgA protease type of exported protein. Mol Microbiol (1994) 3.47
Cloning and genetic characterization of a Helicobacter pylori flagellin gene. Mol Microbiol (1992) 2.97
Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid. Biochemistry (1986) 2.97
Improved preparation of lipoteichoic acids. Eur J Biochem (1983) 2.61
Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2001) 2.59
A stable shuttle vector system for efficient genetic complementation of Helicobacter pylori strains by transformation and conjugation. Mol Gen Genet (1998) 2.50
Variation and control of protein expression in Neisseria. Annu Rev Microbiol (1990) 2.49
Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene (2000) 2.47
Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology (1994) 2.35
Interaction of two variable proteins (PilE and PilC) required for pilus-mediated adherence of Neisseria gonorrhoeae to human epithelial cells. Mol Microbiol (1992) 2.31
Natural transformation competence in Helicobacter pylori is mediated by the basic components of a type IV secretion system. Mol Microbiol (2001) 2.29
MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein. Gastroenterology (1997) 2.25
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia (2004) 2.08
Genetic and functional characterization of the alpAB gene locus essential for the adhesion of Helicobacter pylori to human gastric tissue. Mol Microbiol (1999) 2.06
Determination of different cytomegalovirus immunoglobulins (IgG, IgA, IgM) by immunofluorescence. Arch Gesamte Virusforsch (1972) 2.04
Reassortment of pilin genes in Neisseria gonorrhoeae occurs by two distinct mechanisms. Nature (1989) 1.98
A plasmid cloning system utilizing replication and packaging functions of the filamentous bacteriophage fd. Gene (1985) 1.97
Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia (2004) 1.90
The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia (2008) 1.89
Linkage-disequilibrium mapping of autistic disorder, with 15q11-13 markers. Am J Hum Genet (1998) 1.87
Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology (1995) 1.77
Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr Med Chem (2004) 1.74
A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability. Nucleic Acids Res (1999) 1.73
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia (2005) 1.72
Evidence of linkage between the serotonin transporter and autistic disorder. Mol Psychiatry (1997) 1.71
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia (2013) 1.71
Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood (1996) 1.70
Helicobacter pylori outer membrane proteins and gastroduodenal disease. Gut (2005) 1.62
Rapid and specific detection of Helicobacter pylori macrolide resistance in gastric tissue by fluorescent in situ hybridisation. Gut (2000) 1.62
A pilot study of bendamustine in elderly patients with high-risk MDS and AML. Leuk Lymphoma (2007) 1.58
Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia (2007) 1.58
Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant (2005) 1.57
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia (2012) 1.57
Activation of activator protein 1 and stress response kinases in epithelial cells colonized by Helicobacter pylori encoding the cag pathogenicity island. J Biol Chem (1999) 1.54
SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia (2013) 1.50
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia (2010) 1.48
The role of lipoteichoic acid biosynthesis in membrane lipid metabolism of growing Staphylococcus aureus. Eur J Biochem (1984) 1.48
DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology. Cancer Res (2001) 1.46
Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia (1992) 1.45
Hemodynamic effect of carotid endarterectomy. Stroke (1987) 1.45
Natural competence for DNA transformation in Helicobacter pylori: identification and genetic characterization of the comB locus. Mol Microbiol (1998) 1.45
Searches for Lepton flavor violation in the decays tau{+/-}-->e{+/-}gamma and tau{+/-}-->mu{+/-}gamma. Phys Rev Lett (2010) 1.44
Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis. Bone Marrow Transplant (1994) 1.43
Pericardial effusion in chronic myelomonocytic leukemia (CMML): a case report and review of the literature. Leuk Res (2000) 1.42
Identification of amine components in a glycolipid membrane-binding domain at the C-terminus of human erythrocyte acetylcholinesterase. Biochemistry (1986) 1.41
Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia. Cytotherapy (2004) 1.41
Are self-expanding stents superior to balloon-expanded in dilating aortas? An experimental study in pigs. Eur J Vasc Endovasc Surg (1996) 1.40
High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. Ann Oncol (1997) 1.39
Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia (2013) 1.39
Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits. Infect Immun (1998) 1.38
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia (2013) 1.37
Cloning and genetic characterization of Helicobacter pylori catalase and construction of a catalase-deficient mutant strain. J Bacteriol (1996) 1.35
Optimized BlaM-transposon shuttle mutagenesis of Helicobacter pylori allows the identification of novel genetic loci involved in bacterial virulence. Mol Microbiol (1996) 1.34
Interaction of Helicobacter pylori with professional phagocytes: role of the cag pathogenicity island and translocation, phosphorylation and processing of CagA. Cell Microbiol (2001) 1.33
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia (2012) 1.33
Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine (1998) 1.32
Growth and relaxation processes in Ge nanocrystals on free-standing Si(001) nanopillars. Nanotechnology (2012) 1.32
Noncytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. Dis Colon Rectum (1992) 1.31
Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol (2001) 1.30
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia (2004) 1.28
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia (2012) 1.27
Fate in intermittent claudication: outcome and risk factors. Br Med J (Clin Res Ed) (1986) 1.26
Infection by Helicobacter pylori expressing the BabA adhesin is influenced by the secretor phenotype. J Pathol (2008) 1.26
Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. Ann Oncol (2010) 1.26
Measurement of chemopreventive efficacy in skin biopsies. Anal Quant Cytol Histol (2001) 1.25
Cloning of the Helicobacter pylori recA gene and functional characterization of its product. Mol Gen Genet (1995) 1.25
Encoding of movement time by populations of cerebellar Purkinje cells. Nature (2000) 1.24
Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia (2013) 1.23
The 5q- syndrome. Hematology (2004) 1.23
Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol (2009) 1.22
Relationship between airway narrowing, patchy ventilation and lung mechanics in asthmatics. Eur Respir J (2007) 1.20
Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia (2007) 1.20
Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk Res (2008) 1.19
Mouse thymidine kinase: the promoter sequence and the gene and pseudogene structures in normal cells and in thymidine kinase deficient mutants. Nucleic Acids Res (1989) 1.18